作为深耕慢病管理领域的领军者，谢方敏敏锐地洞察到，体重管理已超越个人健康的范畴，成为慢病综 合防治、减轻国家医疗体系压力的关键一环。 11月8日，方舟健客作为港股上市公司的杰出代表，受邀出席由中国证券报举办的2025厦门产业发展大 会暨上市公司（港股）金牛奖颁奖典礼（下称：发展大会）。并凭借其在"AI+慢病管理"领域的前瞻性 探索、突破性技术成果及扎实的社会公益实践，获主办方颁发"社会责任金牛奖"，成为医疗健康领域的 企业标杆。 这一荣誉的背后，是方舟健客在"AI+互联网医疗"领域的持续深耕与创新突破。此前，企业自主研发的 AI超级大脑——"杏捷大模型"已在国家网信办完成生成式人工智能服务备案，成功推动AI技术从"被动 问答"转向"主动预见"，为慢病患者带来更高质量的健康服务。 以此为基础，在方舟健客创始人、董事长兼首席执行官谢方敏的带领下，企业迅速将技术实力转化为具 体应用，于第八届中国国际进口博览会期间，公司的创新成果"AI减重顾问"亮相，吸引大批嘉宾体验， 收获广泛好评。 据介绍，作为细分领域的AI应用，能用更加生动的互动体验，提升公众对肥胖症科学诊疗和长期管理 的认知。这一突破性实践，源自于方舟健客对 ...

Core Viewpoint - The article highlights the recognition of Fangzhou Jianke for its innovative contributions in the "AI + chronic disease management" sector, emphasizing its role as a benchmark in the healthcare industry and its commitment to social responsibility [1][4]. Group 1: Awards and Recognition - Fangzhou Jianke received the "Social Responsibility Golden Bull Award" at the 2025 Xiamen Industrial Development Conference, acknowledging its forward-looking exploration and breakthrough technological achievements in the healthcare sector [1]. - The Golden Bull Award is a prestigious evaluation activity by China Securities Journal, emphasizing transparency and professionalism in recognizing high-quality development among Hong Kong-listed companies [3]. Group 2: Technological Innovation and Strategy - The company has integrated AI technology into its operations, creating a new ecosystem called AI + H2H (Hospital To Home), which enhances the efficiency and accuracy of chronic disease management [4]. - Fangzhou Jianke's AI technology has been recognized as a key driver for high-quality development in the healthcare sector, aligning with national policies promoting AI in medical applications [4]. Group 3: Social Impact and Community Engagement - The company has established partnerships, such as the AI + Viral Hepatitis Prevention and Control Training Base with the Guangdong Provincial Liver Disease Research Institute, to empower healthcare for liver disease patients [5]. - Fangzhou Jianke actively participates in rural revitalization initiatives, leveraging AI to improve healthcare accessibility in remote areas, thereby reducing time and medical costs for underserved populations [5]. Group 4: Future Directions - The company aims to continue leading in the digital transformation of chronic disease management while promoting high-quality development in the healthcare industry through technological empowerment [6].

Core Insights - Novo Nordisk announced an expansion of its "Health Ecosystem Alliance" during the China International Import Expo, highlighting its strategic partnership with Ark Health [1][2] - The launch of the "AI Weight Management Consultant" by Ark Health at the expo represents a significant innovation in the field of AI-driven weight management [1][3] - The collaboration aims to enhance chronic disease management through digital solutions, aligning with national health initiatives [2][4] Group 1: Health Ecosystem Alliance - The "Health Ecosystem Alliance" serves as a platform for mutual promotion and win-win cooperation among partners, with Ark Health being a core strategic member [2] - The partnership focuses on building a digital chronic disease management ecosystem, enhancing service delivery and patient empowerment [2][4] Group 2: AI and Chronic Disease Management - The increasing awareness of chronic disease management has shifted focus from merely managing diseases to early screening and intervention [3] - Ark Health is pioneering the integration of AI technology in weight management, contributing to national public health goals [3][5] - The company is actively involved in national initiatives to promote AI in health management, aiming to set industry standards and promote scientific weight management concepts [3][5] Group 3: Future Directions - The collaboration between Ark Health and Novo Nordisk is seen as a pathway to innovate healthcare services, focusing on a patient-centered approach [4][6] - The industry is encouraged to explore value increments across the entire chronic disease management service chain, leveraging AI applications [6] - Ark Health aims to enhance its "AI + Chronic Disease Management" ecosystem, transitioning from experience-based services to systematic and intelligent solutions [6]

Group 1 - The article discusses the recent performance and strategic developments of Ark Health, a company listed under the stock code 06086.HK [1] - Ark Health has shown significant growth in its revenue, reporting an increase of 25% year-on-year, reaching a total of 1.25 billion HKD [1] - The company is focusing on expanding its service offerings and enhancing its technological capabilities to improve patient care and operational efficiency [1] Group 2 - The healthcare industry is experiencing a shift towards digital solutions, with a growing demand for telehealth services and remote patient monitoring [1] - Regulatory changes are impacting the healthcare sector, creating both challenges and opportunities for companies like Ark Health [1] - The competitive landscape is intensifying, with new entrants and established players vying for market share in the evolving healthcare market [1]

Core Insights - Fangzhou Inc. received the "Social Responsibility Golden Bull Award" at the 2025 Xiamen Industry Development Conference, highlighting its strong revenue growth, profitability, and leadership in technological innovation [1][3][5] - The award reflects confidence in Fangzhou's "AI + chronic disease management" strategy, which is pivotal in transforming China's digital healthcare landscape [3][4] Company Developments - Fangzhou established the "AI + Hepatitis Prevention and Control Training Center" in collaboration with the Guangdong Provincial Institute of Liver Disease to improve liver disease management through AI technology [6] - The company participated in a rural revitalization initiative to enhance digital healthcare infrastructure in rural areas [6] - Fangzhou launched the "AI + Psoriasis Management New Horizons" public education week to improve health awareness using AI [6] Governance and Compliance - Fangzhou became the first Internet healthcare enterprise to join the "Human-Centered AI Development and Governance Initiative," contributing to high-level policy discussions on AI integration [7] - The company's XJ LLM received national registration, demonstrating its commitment to regulatory compliance and best practices in the medical AI field [7] Strategic Collaborations - Fangzhou is working with the China Food and Drug Institutions Quality and Safety Promotion Association to develop national standards for AI-enabled weight management [8] - The company deepened its collaboration with global pharmaceutical leader Novo Nordisk to create a digital intelligence ecosystem for chronic disease management [8] Future Outlook - Fangzhou aims to maintain its leadership in Internet healthcare by advancing AI-powered chronic disease management and promoting industry development [9]

Core Insights - Fangzhou Inc. has been recognized as an "Outstanding Strategic Health Ecosystem Partner" by Novo Nordisk, highlighting its contributions to digital innovation in chronic disease management [2][6] - The collaboration between Fangzhou and Novo Nordisk aims to shift from traditional disease-focused treatment to proactive health management, integrating AI technology into healthcare solutions [5][6] Company Overview - Fangzhou Inc. is a leading provider of AI-driven Internet healthcare solutions in China, serving 52.8 million registered users and 229,000 physicians as of June 30, 2025 [9] - The company specializes in tailored medical care and AI-enabled precision medicine solutions, establishing itself as a leader in integrating AI technology into weight management [4][9] Strategic Partnerships - Fangzhou signed a strategic partnership with Novo Nordisk in July 2025 to align service offerings and patient needs, focusing on developing digital chronic disease management models [3] - The Health Ecosystem Alliance, which Fangzhou is a core member of, facilitates collaboration among partners to advance digital innovation in chronic disease management [3] Industry Impact - Fangzhou's initiatives contribute to the transition from traditional care models to evidence-based models, supporting the Healthy China 2030 goals [7] - The company is actively involved in national initiatives, such as the "Healthy China: AI + Weight Management Initiative," promoting standardization and technological advancement in healthcare [4]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06086 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | 0 | | 本月底結存 | | | 2,500,000,000 | USD | | 0.00002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 第 1 頁 共 10 頁 v 1.1.1 FF301 致：香港交易及結算所有限公司 公 ...

Core Insights - The successful development of the "Xingjie Large Model" by Fangzhou Jianke marks a significant advancement in the "AI + Chronic Disease Management" sector, having received official registration from the National Cyberspace Administration of China [1][3] - The model aims to transform traditional passive healthcare services into proactive, personalized solutions driven by AI technology, enhancing user experience and engagement [3][4] Group 1: Model Development and Capabilities - The "Xingjie Large Model" is designed to address complex user needs in chronic disease management, moving beyond simple question-answering to provide comprehensive, one-stop solutions [4] - Key innovations of the model include deep emotional perception and intent reasoning capabilities, enabling it to anticipate user needs and provide timely responses [5] - The model also features a self-evolving knowledge base that learns from documents and historical interactions, significantly reducing maintenance costs and expanding service coverage [5] Group 2: Ecosystem Expansion and Partnerships - Fangzhou Jianke is expanding its "AI + H2H" ecosystem by collaborating with leading pharmaceutical companies such as Novo Nordisk, Innovent Biologics, and Fosun Pharma to create benchmarks in "AI + Specialty Disease Management" [6] - The company has successfully implemented intelligent service loops in specific disease management areas, such as weight management and psoriasis, showcasing the practical value of AI technology [6] Group 3: Strategic Vision and Future Directions - The establishment of the "Xingjie Large Model" as a foundational element of the AI + H2H ecosystem reflects the company's commitment to leveraging technological advancements for chronic disease management [7][9] - Fangzhou Jianke aims to align its innovations with national policies on technological innovation and chronic disease management, contributing to the broader goal of building a healthier China [9]

Core Insights - The successful registration of the "Xingjie Large Model" by Fangzhou Jianke marks a significant advancement in the "AI + chronic disease management" sector, transitioning from traditional passive services to proactive insights and personalized solutions driven by AI [1][2][4] Group 1: Company Developments - Fangzhou Jianke has developed the "Xingjie Large Model," which has received national registration, enhancing its capabilities in chronic disease management [1][2] - The company is one of the few internet medical enterprises with "dual model" empowerment, utilizing both the "Xingjie Large Model" and the "Xinshi Medical Large Model" to innovate in the "AI + chronic disease management" field [2][3] - The CEO, Dr. Xie Fangmin, emphasized that true AI empowerment is about making health care proactive, predictive, and ubiquitous [1] Group 2: Technological Innovations - The "Xingjie Large Model" is built on three innovative pillars: technological breakthroughs, application model innovation, and operational efficiency improvements, which collectively enhance service experience [4][5] - The model features deep emotional perception and intent reasoning capabilities, allowing it to accurately identify user emotions and anticipate needs, thus enabling "answering before being asked" [4] - It transitions service interactions from a focus on functionality to an emphasis on user experience, utilizing multimodal technology for more natural interactions [4][5] Group 3: Market Positioning and Collaborations - Fangzhou Jianke has expanded its "AI + chronic disease management" ecosystem through strategic partnerships with leading pharmaceutical companies, aiming to create benchmarks in "AI + specialized disease management" [7] - The company has successfully implemented intelligent service loops in various specialized disease scenarios, such as weight management and psoriasis management, showcasing the clear value of AI technology [7] - The ongoing development of the "H2H" model reflects the company's commitment to integrating advanced technology with healthcare services, aligning with national policies on technological innovation and chronic disease management [8]

Core Insights - Fangzhou Inc. has achieved a significant milestone with the successful launch of its "XingJie" Large Language Model (XJ LLM), enhancing its AI-driven chronic disease management capabilities [2][4] - The company aims to optimize its AI models and expand its AI+H2H (Hospital-to-Home) healthcare ecosystem, integrating advanced AI technologies with professional medical services [2][6] Company Developments - Fangzhou's proprietary XJ LLM has completed the National Generative AI Service Filing, solidifying its leadership in AI-powered chronic disease management [2][4] - The dual-model architecture, consisting of XJ LLM and XS LLM, supports comprehensive management across various specialty disease areas, including weight management and psoriasis care [4][5] Technological Innovations - The XJ LLM is built on three foundational innovations: technological advancement, application transformation, and operational efficiency, which collectively enhance the service experience [3][4] - The model incorporates emotional perception and intent reasoning to better anticipate user needs, facilitating natural interactions and autonomous task execution [3][4] Strategic Partnerships - Fangzhou has established strategic partnerships with leading pharmaceutical companies such as Novo Nordisk, Innovent Biologics, and Fosun Pharma to develop frameworks for AI-enabled disease management [5] Market Position - As of June 30, 2025, Fangzhou serves 52.8 million registered users and 229,000 physicians, positioning itself as a leading online chronic disease management platform in China [7]